qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver

Description

The purpose of this research is to evaluate a new technique, quantitative digital subtraction angiography (qDSA), to measure blood flow during liver embolization procedures. Liver transarterial embolization is a way of treating liver tumors by blocking blood flow to it. The qDSA technique could help doctors ensure the blood flow to the tumor is decreased by the right amount by calculating blood flow before, during, and after the procedure. Up to 20 participants will be enrolled for 1 study visit and data collection for up to 6 months.

Conditions

Transarterial Embolism, Transarterial Chemoembolization

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research is to evaluate a new technique, quantitative digital subtraction angiography (qDSA), to measure blood flow during liver embolization procedures. Liver transarterial embolization is a way of treating liver tumors by blocking blood flow to it. The qDSA technique could help doctors ensure the blood flow to the tumor is decreased by the right amount by calculating blood flow before, during, and after the procedure. Up to 20 participants will be enrolled for 1 study visit and data collection for up to 6 months.

qDSA Blood Flow Measurement in Patients Undergoing Transarterial Embolization (TAE) of the Liver

qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver

Condition
Transarterial Embolism
Intervention / Treatment

-

Contacts and Locations

Madison

UW Hospital and Clinics, Madison, Wisconsin, United States, 53792

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Give voluntary, written informed consent to participate in this study and willing to comply with study-related evaluation and procedure schedule
  • * Pregnancy or breastfeeding
  • * Patients with an acute kidney injury or stage IV or V chronic kidney disease (Cr greater than 2.4 or estimated glomerular filtration rate (eGFR) less than 30), unless anuric and on dialysis without expected return of renal function.
  • * Patients with an iodinated contrast allergy who cannot be adequately premedicated to receive contrast as part of the embolization procedure.
  • * Patients with a physical or psychological condition that would impair study participation.
  • * The patient is judged unsuitable for study participation by the Investigator for any other reason

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Wisconsin, Madison,

Paul Laeseke, MD, PhD, PRINCIPAL_INVESTIGATOR, UW School of Medicine and Public Health

Study Record Dates

2026-03